Replies to post #301602 on NorthWest Biotherapeutics Inc (NWBO)

[JerryCampbell]

If it is not confirmed by a statistically significant difference between treatment and control, the blended/blinded data is meaningless. That is how you prove a drug works.

If the control cohort and treatment cohort both lived longer than expected, then nwbo is back to square zero.

[biosectinvestor]

Yes. Exactly!

[GoodGuyBill]

You've got that exactly right...and those stats speak louder than all of the bs they post 24/7 day after day after day after day. GLTU.

Median OS From Surgery 95% Confidence Interval
2017 data 40.4 months 35.5 – 46.5 months
2018 data 58.4 months 45.9 – 94.5 months
The survival of the top 100 patients does not appear to be fully explained by known prognostic factors.-- CherryTree1

[reachjo]

You nailed it! Anyone who understands clinical oncology trials understands why it’s mind blowing no matter how you cut it.

[TopelRoad]

Assuming PFS failed, the study is not a routine gold standard double blind, which is why critics are crying failure.
However, the crossover placebo is still a comparison group. There should be enough elapsed time to see separation. I think the company must think they may have separation.

It’s still a challenging regulatory submission / strategy.